Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111497 · ClinicalTrials.gov registry record · Phase 1
Glasdegib for Chronic Graft-Versus-Host Disease
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04111497 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 15 participants.
The verdict
NCT04111497, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.
Interventions
- DRUG Glasdegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111497
The ClinicalTrials.gov registry entry for NCT04111497 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glasdegib is the first listed.
NCT04111497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111497 about?
NCT04111497 is a clinical study titled "Glasdegib for Chronic Graft-Versus-Host Disease". This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.
What is the current status of trial NCT04111497?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-12-03. Estimated completion is 2023-08-23.
What interventions are being tested in trial NCT04111497?
The interventions under investigation include: Glasdegib (DRUG).
Who is sponsoring clinical trial NCT04111497?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.